Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
As more non-weight indications emerge, including potential applications for addiction, Alzheimer disease, fatty liver disease, and chronic kidney disease, the relevance of BMI as the primary gatekeeper will diminish
they can provide a renewed sense of hope and motivation
For weight management, some patients may attempt discontinuation after achieving goals, though most will require ongoing treatment to maintain weight loss
BMJ Open 9(5):e024065
Tirzepatide injection timing Tirzepatide has a half-life of approximately 5 days, slightly shorter than semaglutide but still producing week-long therapeutic activity from a weekly injection
DPP-4 inhibitors are increasingly replacing sulfonylureas as insulinotropic agents, but they can frequently also be a good therapeutic alternative to other treatment options such as glitazones or glucosidase inhibitors
